N-(2,3,5,6-Tetramethyl-4-nitro-phenyl)-formamide | 16618-62-5

• 英文名称: N-(2,3,5,6-Tetramethyl-4-nitro-phenyl)-formamide
• 英文别名: N-(2,3,5,6-tetramethyl-4-nitrophenyl)formamide
• CAS: 16618-62-5
• 化学式: C₁₁H₁₄N₂O₃
• 分子量: 222.244
• InChiKey: UZHBLOHCEHEGOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE SULFONYLURÉES SUBSTITUÉS
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2019043610A1

  公开（公告）日：2019-03-07

  The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.

  本发明涉及一种新型杂环化合物，其一般式为（I），以及它们的药物可接受的盐、药物可接受的溶剂化物、对映体、非对映体异构体和多晶形。本发明还涉及制备本发明化合物的方法、含有该化合物的制药组合物以及它们作为NOD样受体家族（NLR）蛋白NLRP3调节剂的应用。因此，本发明涉及新型NLRP3调节剂以及在治疗由NLRP3介导的疾病或病情以及与白细胞介素1β活性和白细胞介素18（IL-18）有关的疾病或病情的治疗中使用新型抑制剂化合物。